# Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus

> **NCT06227221** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 10 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06227221
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2028-10
- **Final completion:** 2029-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06227221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06227221, "Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06227221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*